<p>根據最近向證券交易委員會的披露，Exchange Traded Concepts LLC 在第三季度將其在 CVS Health Corporation（紐約證券交易所代碼：CVS - 免費報告）的持股增加了 86.7%。該基金在此期間購買了額外的 15,927 股後，持有 34,298 股該藥房運營商的股票。根據其最近向證券交易委員會的備案，Exchange Traded Concepts LLC 在 CVS Health 的持股價值為 2,586,000 美元。</p>
<ul>
<li>CVS Health 因收入增長而獲利，股息保持強勁</li>
</ul>
<p>其他一些機構投資者和對沖基金最近也買賣了該公司的股票。挪威銀行在第二季度購買了 CVS Health 的新頭寸，價值約為 1,358,698,000 美元。Invesco Ltd.在第二季度將其在 CVS Health 的持股增加了 15.3%。Invesco Ltd.現在擁有 23,532,479 股該藥房運營商的股票，價值 1,623,270,000 美元，此前在上個季度購買了額外的 3,118,626 股。Robeco Institutional Asset Management B.V.在第二季度將其在 CVS Health 的頭寸提升了 815.2%。Robeco Institutional Asset Management B.V.現在擁有 2,663,111 股該藥房運營商的股票，價值 183,701,000 美元，此前在上個季度購買了額外的 2,372,121 股。Kingstone Capital Partners Texas LLC 在第二季度獲得了 CVS Health 的新頭寸，價值 155,185,000 美元。最後，Jennison Associates LLC 在第二季度將其在 CVS Health 的持股增加了 111.7%。Jennison Associates LLC 現在擁有 4,014,139 股該藥房運營商的股票，價值 276,895,000 美元，此前在上個季度購買了額外的 2,117,798 股。目前，80.66% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師評級變動</h2>
<p>幾位研究分析師最近對該股票進行了評估。Wolfe Research 將 CVS Health 的股票目標價從 85.00 美元上調至 100.00 美元，並在 12 月 8 日的研究報告中給予該公司 “跑贏大盤” 的評級。Weiss Ratings 在週一的報告中重申了對 CVS Health 的 “持有（c-）” 評級。摩根大通在 12 月 17 日的報告中將 CVS Health 的股票目標價從 93.00 美元上調至 101.00 美元，並給予該股票 “增持” 評級。Evercore ISI 在 10 月 30 日的報告中將 CVS Health 的目標價從 85.00 美元上調至 95.00 美元，並給予該公司 “跑贏大盤” 的評級。最後，Cantor Fitzgerald 在 12 月 10 日的研究報告中重申了對 CVS Health 的 “增持” 評級。有兩位股票研究分析師給予該股票 “強烈買入” 評級，二十位給予 “買入” 評級，四位給予 “持有” 評級。根據 MarketBeat，該公司的平均評級為 “適度買入”，平均目標價為 94.67 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 05/12 - 05/16</li>
</ul>
<p><strong>查看我們對 CVS 的最新分析</strong></p>
<h2>CVS Health 股票表現</h2>
<p>CVS 股票在週五開盤價為 79.06 美元。CVS Health Corporation 的年低為 43.65 美元，年高為 85.15 美元。該公司的債務與股本比率為 0.83，速動比率為 0.63，流動比率為 0.83。該公司的 50 日移動平均價格為 78.97 美元，200 日移動平均價格為 72.79 美元。該公司的市值為 1003.5 億美元，市盈率為 208.04，市盈增長比率為 0.78，貝塔值為 0.48。</p>
<ul>
<li>現在是購買 Novo Nordisk 股票的時機嗎？</li>
</ul>
<p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最近在 10 月 29 日宣佈了其財報。該藥房運營商報告本季度每股收益（EPS）為 1.60 美元，超出分析師共識預期的 1.36 美元，超出幅度為 0.24 美元。CVS Health 的股本回報率為 11.45%，淨利潤率為 0.12%。該公司本季度的收入為 1028.7 億美元，而分析師預期為 988.5 億美元。在去年同期，該公司每股收益為 1.09 美元。該公司的季度收入較去年同期增長了 7.8%。CVS Health 已將其 2025 財年的指導目標設定為每股收益 6.550-6.650 美元。整體而言，股票研究分析師預測 CVS Health Corporation 在當前年度將發佈 5.89 美元的每股收益。</p>
<h2>CVS Health 簡介</h2>
<p>（免費報告）</p>
<p>CVS Health Corporation 是一家多元化的醫療保健公司，運營着一個大型零售藥房網絡、藥房福利管理服務和醫療解決方案。公司總部位於羅德島州的伍恩索克特，追溯其根源至 20 世紀 60 年代初，已發展成為一個綜合的處方藥、非處方產品、臨牀服務和健康保險提供商。其運營模式結合了零售藥房位置和店內診所，以及更廣泛的藥房和健康計劃能力。</p>
<p>主要業務活動包括 CVS 藥房零售業務、MinuteClinic 步入式醫療診所和提供擴展臨牀服務的 HealthHUB 地點。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票超過 CVS Health</li>
<li>在 1 月 1 日之前投入 1,000 美元到這隻股票中 [不是 NVDA]</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓為戰爭做準備</li>
<li>奇怪的水晶金屬表現優於硅達 100 倍</li>
<li>來自奇怪的新 “AI 燃料” 的 33,000% 繁榮</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元到 CVS Health 嗎？</h2>
<p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 CVS Health 並不在名單上。</p>
<p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

西維斯

<p>Exchange Traded Concepts LLC 在第三季度將其在 CVS Health Corporation 的持股增加了 86.7%，目前擁有 34,298 股，價值 259 萬美元。其他機構投資者也調整了他們的持倉。分析師對 CVS Health 給予了 “適度買入” 的評級，目標價格為 94.67 美元。CVS 報告第三季度每股收益為 1.60 美元，超出預期，收入同比增長 7.8%。該公司運營着一個大型的零售藥房和醫療服務網絡</p>

<p>Exchange Traded Concepts LLC grew its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 86.7% in the third quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 34,298 shares of the pharmacy operator's stock after buying an additional 15,927 shares during the period. Exchange Traded Concepts LLC's holdings in CVS Health were worth $2,586,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>根據最近向證券交易委員會的披露，Exchange Traded Concepts LLC 在第三季度將其在 CVS Health Corporation（紐約證券交易所代碼：CVS - 免費報告）的持股增加了 86.7%。該基金在此期間購買了額外的 15,927 股後，持有 34,298 股該藥房運營商的股票。根據其最近向證券交易委員會的備案，Exchange Traded Concepts LLC 在 CVS Health 的持股價值為 2,586,000 美元。</p>
</div><ul>
<li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li>
</ul>
<div class="lb-trans"><ul>
<li>CVS Health 因收入增長而獲利，股息保持強勁</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Norges Bank purchased a new position in CVS Health in the 2nd quarter worth approximately $1,358,698,000. Invesco Ltd. increased its holdings in shares of CVS Health by 15.3% in the second quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator's stock valued at $1,623,270,000 after purchasing an additional 3,118,626 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in CVS Health by 815.2% during the second quarter. Robeco Institutional Asset Management B.V. now owns 2,663,111 shares of the pharmacy operator's stock worth $183,701,000 after buying an additional 2,372,121 shares in the last quarter. Kingstone Capital Partners Texas LLC acquired a new position in CVS Health during the second quarter worth $155,185,000. Finally, Jennison Associates LLC grew its holdings in CVS Health by 111.7% in the 2nd quarter. Jennison Associates LLC now owns 4,014,139 shares of the pharmacy operator's stock valued at $276,895,000 after buying an additional 2,117,798 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也買賣了該公司的股票。挪威銀行在第二季度購買了 CVS Health 的新頭寸，價值約為 1,358,698,000 美元。Invesco Ltd.在第二季度將其在 CVS Health 的持股增加了 15.3%。Invesco Ltd.現在擁有 23,532,479 股該藥房運營商的股票，價值 1,623,270,000 美元，此前在上個季度購買了額外的 3,118,626 股。Robeco Institutional Asset Management B.V.在第二季度將其在 CVS Health 的頭寸提升了 815.2%。Robeco Institutional Asset Management B.V.現在擁有 2,663,111 股該藥房運營商的股票，價值 183,701,000 美元，此前在上個季度購買了額外的 2,372,121 股。Kingstone Capital Partners Texas LLC 在第二季度獲得了 CVS Health 的新頭寸，價值 155,185,000 美元。最後，Jennison Associates LLC 在第二季度將其在 CVS Health 的持股增加了 111.7%。Jennison Associates LLC 現在擁有 4,014,139 股該藥房運營商的股票，價值 276,895,000 美元，此前在上個季度購買了額外的 2,117,798 股。目前，80.66% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several research analysts have recently weighed in on the stock. Wolfe Research boosted their price target on shares of CVS Health from $85.00 to $100.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, December 8th. Weiss Ratings reiterated a &#34;hold (c-)&#34; rating on shares of CVS Health in a report on Monday. JPMorgan Chase &amp; Co. raised their price target on shares of CVS Health from $93.00 to $101.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, December 17th. Evercore ISI upped their price objective on CVS Health from $85.00 to $95.00 and gave the company an &#34;outperform&#34; rating in a report on Thursday, October 30th. Finally, Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of CVS Health in a research report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $94.67.</p>
<div class="lb-trans"><p>幾位研究分析師最近對該股票進行了評估。Wolfe Research 將 CVS Health 的股票目標價從 85.00 美元上調至 100.00 美元，並在 12 月 8 日的研究報告中給予該公司 “跑贏大盤” 的評級。Weiss Ratings 在週一的報告中重申了對 CVS Health 的 “持有（c-）” 評級。摩根大通在 12 月 17 日的報告中將 CVS Health 的股票目標價從 93.00 美元上調至 101.00 美元，並給予該股票 “增持” 評級。Evercore ISI 在 10 月 30 日的報告中將 CVS Health 的目標價從 85.00 美元上調至 95.00 美元，並給予該公司 “跑贏大盤” 的評級。最後，Cantor Fitzgerald 在 12 月 10 日的研究報告中重申了對 CVS Health 的 “增持” 評級。有兩位股票研究分析師給予該股票 “強烈買入” 評級，二十位給予 “買入” 評級，四位給予 “持有” 評級。根據 MarketBeat，該公司的平均評級為 “適度買入”，平均目標價為 94.67 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 05/12 - 05/16</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 05/12 - 05/16</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on CVS</strong></p>
<div class="lb-trans"><p><strong>查看我們對 CVS 的最新分析</strong></p>
</div><h2>CVS Health Stock Performance</h2>
<div class="lb-trans"><h2>CVS Health 股票表現</h2>
</div><p>Shares of CVS stock opened at $79.06 on Friday. CVS Health Corporation has a one year low of $43.65 and a one year high of $85.15. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.63 and a current ratio of 0.83. The firm's 50 day moving average price is $78.97 and its 200-day moving average price is $72.79. The firm has a market cap of $100.35 billion, a P/E ratio of 208.04, a P/E/G ratio of 0.78 and a beta of 0.48.</p>
<div class="lb-trans"><p>CVS 股票在週五開盤價為 79.06 美元。CVS Health Corporation 的年低為 43.65 美元，年高為 85.15 美元。該公司的債務與股本比率為 0.83，速動比率為 0.63，流動比率為 0.83。該公司的 50 日移動平均價格為 78.97 美元，200 日移動平均價格為 72.79 美元。該公司的市值為 1003.5 億美元，市盈率為 208.04，市盈增長比率為 0.78，貝塔值為 0.48。</p>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>現在是購買 Novo Nordisk 股票的時機嗎？</li>
</ul>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.24. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The company had revenue of $102.87 billion for the quarter, compared to analyst estimates of $98.85 billion. During the same quarter in the previous year, the company earned $1.09 earnings per share. The firm's quarterly revenue was up 7.8% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. As a group, equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current year.</p>
<div class="lb-trans"><p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最近在 10 月 29 日宣佈了其財報。該藥房運營商報告本季度每股收益（EPS）為 1.60 美元，超出分析師共識預期的 1.36 美元，超出幅度為 0.24 美元。CVS Health 的股本回報率為 11.45%，淨利潤率為 0.12%。該公司本季度的收入為 1028.7 億美元，而分析師預期為 988.5 億美元。在去年同期，該公司每股收益為 1.09 美元。該公司的季度收入較去年同期增長了 7.8%。CVS Health 已將其 2025 財年的指導目標設定為每股收益 6.550-6.650 美元。整體而言，股票研究分析師預測 CVS Health Corporation 在當前年度將發佈 5.89 美元的每股收益。</p>
</div><h2>CVS Health Profile</h2>
<div class="lb-trans"><h2>CVS Health 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.</p>
<div class="lb-trans"><p>CVS Health Corporation 是一家多元化的醫療保健公司，運營着一個大型零售藥房網絡、藥房福利管理服務和醫療解決方案。公司總部位於羅德島州的伍恩索克特，追溯其根源至 20 世紀 60 年代初，已發展成為一個綜合的處方藥、非處方產品、臨牀服務和健康保險提供商。其運營模式結合了零售藥房位置和店內診所，以及更廣泛的藥房和健康計劃能力。</p>
</div><p>Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.</p>
<div class="lb-trans"><p>主要業務活動包括 CVS 藥房零售業務、MinuteClinic 步入式醫療診所和提供擴展臨牀服務的 HealthHUB 地點。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Strange Crystal Metal Outperforms Silicon Up to 100X</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 CVS Health</li>
<li>在 1 月 1 日之前投入 1,000 美元到這隻股票中 [不是 NVDA]</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓為戰爭做準備</li>
<li>奇怪的水晶金屬表現優於硅達 100 倍</li>
<li>來自奇怪的新 “AI 燃料” 的 33,000% 繁榮</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元到 CVS Health 嗎？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CVS Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 CVS Health 並不在名單上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Exchange Traded Concepts LLC 增加了在西維斯健康公司 $CVS 的持倉